Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry-possibilities and limitations

Cytometry Part A

Volumn 77, Issue 4, 2010, Pages 387-398

  Vollmann Zwerenz, Arabel ^a   Diermeier Daucher, Simone ^a   Wege, Anja Kathrin ^a   Sassen, Andrea ^a   Schmidt Brücken, Elisabeth ^a   Hofstaedter, Ferdinand ^a   Ortmann, Olaf ^a   Nauwelaers, Frans ^b   Brockhoff, Gero ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b BD Biosciences ^*  (Belgium)

Author keywords

DNA assessment; Multiparametric flow cytometry; Receptor tyrosine kinases; Solid tumor dissociation

Indexed keywords

DNA; PROTEIN TYROSINE KINASE;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BREAST TUMOR; CELL STRAIN 3T3; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; PHENOTYPE; STAINING; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; NIH 3T3 CELLS; PHENOTYPE; RECEPTOR PROTEIN-TYROSINE KINASES; STAINING AND LABELING;

EID: 77949799244     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20868     Document Type: Article

References (36)

1. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 2008;68:5878-5887.
2. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-1542.
3. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE 2008;3:e2881.
4. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441.
5. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1/EGFR. HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008;10:R2.
6. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004;6:R246-R251.
7. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
8. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-2168.
9. Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstädter F, Schwarz S, Brockhoff G. Absence of HER4 protein associates with decreased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 2009;11: R50.
10. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
11. Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-4225.
12. Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005;205:577-584.
13. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
14. Chattopadhyay PK, Hogerkorp CM, Roederer M. A chromatic explosion: The development and future of multiparameter flow cytometry. Immunology 2008;125:441-449.
15. Chattopadhyay PK, Price DA, Harper TF, Betts MR, Yu J, Gostick E, Perfetto SP, Goepfert P, Koup RA, De Rosa SC, Bruchez MP, Roederer M. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med 2006;12:972-977.
16. Plander M, Brockhoff G, Barlage S, Schwarz S, Rothe G, Knuechel R. Optimization of three- and four-color multiparameter DNA analysis in lymphoma specimens. Cytometry Part A 2003;54A:66-74.
17. Brockhoff G, Fleischmann S, Meier A, Wachs FP, Hofstaedter F, Knuechel R. Use of a mechanical dissociation device to improve standardization of flow cytometric cytokeratin DNA measurements of colon carcinomas. Cytometry 1999;38:184-191.
18. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000;243:77-97.
19. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:1384-1393.
20. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:259-268.
21. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl PO, Stal O, Killander D, Jourdan ML, Romain S, Hunsberger B, Baldetorp B. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001;46:121-135.
22. Bergers E, Baak JP, van Diest PJ, Willig AJ, Los J, Peterse JL, Ruitenberg HM, Schapers RF, Somsen JG, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH. Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: Results of the prospective Multicenter Morphometric Mammary Carcinoma Project. Mod Pathol 1997;10:762-768.
23. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Flow cytometric analysis of DNA ploidy in primary, metastatic and recurrent breast cancers. Oncol Rep 2002;9:793-799.
24. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ, Fleuren GJ. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues J Pathol 2005;206:233-241.
25. Corver WE. Multiparameter DNA Flow Cytometry of Human Solid Tumours. Technical Improvements and Applications. 2001. Enschede: PrintPartners Ipskamp; ISBN: 90-9015213-X.
26. Leers MP, Hoop JG, Nap M. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: Comparison of immunohistochemistry and multiparameter DNA flow cytometry. Anticancer Res 2003;23:999-1006.
27. Corver WE, Cornelisse CJ, Fleuren GJ. Simultaneous measurement of two cellular antigens and DNA using fluorescein-isothiocyanate, R-phycoerythrin, and propidium iodide on a standard FACScan. Cytometry 1994;15:117-128.
28. Corver WE, Bonsing BA, Abeln EC, Vlak-Theil PM, Cornelisse CJ, Fleuren GJ. Onetube triple staining method for flow cytometric analysis of DNA ploidy and phenotypic heterogeneity of human solid tumors using single laser excitation. Cytometry 1996;25:358-366.
29. Corver WE, Fleuren GJ, Cornelisse CJ. Improved single laser measurement of two cellular antigens and DNA-ploidy by the combined use of propidium iodide and TOPRO- 3 iodide. Cytometry 1997;28:329-336.
30. Corver WE, Koopman LA, van der Aa J, Regensburg M, Fleuren GJ, Cornelisse CJ. Four-color multiparameter DNA flow cytometric method to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry 2000;39: 96-107.
31. Leers MP, Schoffelen RH, Hoop JG, Theunissen PH, Oosterhuis JW, vd Bijl H, Rahmy A, Tan W, Nap M. Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol 2002;55:359-366.
32. Nap M, Brockhoff G, Brandt B, Knuechel R, Leers MP, Schmidt H, De Angelis G, Eltze E, Semjonow A. Flow cytometric DNA and phenotype analysis in pathology. A meeting report of a symposium at the annual conference of the German Society of Pathology, Kiel, Germany, 6-9 June 2000. Virchows Arch 2001; 438:425-432.
33. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic significance of the combination of biological parameters in breast cancer. Surg Today 2003;33:151-154.
34. Valet GK, Tarnok A. Cytomics in predictive medicine. Cytometry Part B 2003;53B: 1-3.
35. van Dam PA, Lowe DG, Watson JV, Shepherd JH. Multiparameter flow cytometric measurement of epidermal growth factor receptor and c-erbB-2 oncoprotein in cultured cells and in fresh and preserved solid tumor cells. Int J Gynecol Cancer 1995;5:20-28.
36. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003;133:219-221.